• 274 Citations
  • 9 h-Index
20112019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Elena Geuna is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Breast Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
exemestane Medicine & Life Sciences
Clinical Trials, Phase I Medicine & Life Sciences
N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea Medicine & Life Sciences
Phosphatidylinositol 3-Kinases Medicine & Life Sciences
Hormones Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2011 2019

  • 274 Citations
  • 9 h-Index
  • 21 Article
  • 3 Review article
  • 1 Editorial

What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Giannone, G., Milani, A., Geuna, E., Galizia, D., Biello, F. & Montemurro, F., Jan 2 2019, In : Expert Opinion on Pharmacotherapy. 20, 1, p. 5-9 5 p.

Research output: Contribution to journalEditorial

1 Citation (Scopus)

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

Galizia, D., Milani, A., Geuna, E., Martinello, R., Cagnazzo, C., Foresto, M., Longo, V., Berchialla, P., Solinas, G., Calori, A., Grasso, B., Volpone, C., Bertola, G., Parola, G., Tealdi, G., Giuliano, P. L., Ballari, A. M., Aglietta, M. & Montemurro, F., Sep 1 2018, In : Cancer Medicine. 7, 9, p. 4339-4344 6 p.

Research output: Contribution to journalArticle

Diagnostic Self Evaluation
Adjuvant Chemotherapy
Prospective Studies
Breast Neoplasms
Terminology

What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Giannone, G., Milani, A., Geuna, E., Galizia, D., Biello, F. & Montemurro, F., Nov 6 2018, In : Expert Opinion on Pharmacotherapy. p. 1-5 5 p.

Research output: Contribution to journalArticle

19 Citations (Scopus)

A first-in-human, Phase I, dose-escalation study of TAK-117, A selective PI3Ka isoform inhibitor, in patients with advanced solid malignancies

Juric, D., De Bono, J. S., LoRusso, P. M., Nemunaitis, J., Heath, E. I., Kwak, E. L., Mercade, T. M., Geuna, E., De Miguel-Luken, M. J., Patel, C., Kuida, K., Sankoh, S., Westin, E. H., Zohren, F., Shou, Y. & Tabernero, J., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 5015-5023 9 p.

Research output: Contribution to journalArticle

Protein Isoforms
Neoplasms
Safety
Aspartate Aminotransferases
Alanine Transaminase
Cerebrospinal Fluid
Breast Neoplasms
Neoplasm Metastasis
DNA
Brain